Tirzepatide 20 mg Vial – Dual-Receptor Synthetic Peptide

Tirzepatide is a synthetic 39-amino-acid peptide engineered as a dual agonist of the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This unique combination of receptor activity delivers potent incretin-based signaling, making Tirzepatide a valuable tool for metabolic, obesity, diabetes, and receptor pharmacology studies.

Key Features & Benefits

• Research-grade quality – Supplied as a sterile lyophilized powder for excellent stability and handling convenience.
• Assured purity – ≥99% purity
• Reliable manufacturing
• Optimized for research – Ideal for in vitro assays, receptor binding studies, signaling pathway exploration, and metabolic mechanism analysis.

Composition – 39 amino acids with strategic modifications, including non-coded amino acids (Aib at positions 2 and 13) and lipid conjugation for enhanced half-life and receptor binding.

Mechanism of action – Activates both GLP-1 and GIP receptors, promoting glucose-dependent insulin secretion, regulating glucagon levels, delaying gastric emptying, improving insulin sensitivity, and supporting appetite reduction studies.

Tirzepatide’s dual-agonist properties make it ideal for:

• Evaluating dual GIP/GLP-1 receptor activation in metabolic research.
• Investigating the role of incretin hormones in glucose regulation.
• Exploring novel approaches to appetite and weight control.
• Studying mechanisms underlying insulin sensitivity and energy balance.

Regulatory compliance – For laboratory research use only. Not for human or veterinary consumption.